Inhibrx and bluebird bio began a research collaboration in 2016. Since that time, the collaboration has focused on researching, developing, and commercializing chimeric antigen receptor (CAR) T-cell therapies using Inhibrx’s proprietary single-domain antibody (sdAb) platform to multiple cancer targets.

• In 2018, Inhibrx granted bluebird worldwide rights to develop, manufacture, and commercialize certain cell therapy products.
• In 2020, Inhibrx granted bluebird exclusive worldwide rights to develop binders and cell therapy products containing sdAbs directed to specified targets for two programs and up to an additional eight programs.

In June 2012, Inhibrx and Celgene, now a Bristol-Myers Squibb Company, entered into a Development and Option agreement related to our CD47 checkpoint inhibitor.

In July 2013, Celgene opted to exercise its option and was granted an exclusive global license for the development, manufacture, and commercialization of our proprietary CD47 binding domain.

In 2019, Inhibrx and Chiesi began a collaboration, including an Option Agreement granting an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada, following completion of the Phase 1 trial.

In 2018, Inhibrx and Elpiscience entered into exclusive license agreements for both INBRX-105 and INBRX-106. Elpiscience has rights to these compounds in Greater China, while Inhibrx holds the U.S. and other global rights.

In 2018, Inhibrx and WuXi Biologics partnered to provide biologics development and manufacturing services on a project-by-project basis.

In 2015, Inhibrx and the Alpha-1 Foundation began a collaboration to develop a recombinant alpha-1 antitrypsin therapeutic with improved properties, INBRX-101.